

Inhibitory checkpoint receptors control CD8+ resident memory T cells to prevent skin allergy

Pia Gamradt, Léo Laoubi, Audrey Nosbaum, Virginie Mutez, Vanina Lenief, Sophie Grande, Daniel Redoulès, Anne-Marie Schmitt, Jean-François Nicolas,

Marc Vocanson

► To cite this version:

Pia Gamradt, Léo Laoubi, Audrey Nosbaum, Virginie Mutez, Vanina Lenief, et al.. Inhibitory checkpoint receptors control CD8+ resident memory T cells to prevent skin allergy. Journal of Allergy and Clinical Immunology, 2019, 143, pp.2147 - 2157.e9. 10.1016/j.jaci.2018.11.048 . hal-03486898

HAL Id: hal-03486898 https://hal.science/hal-03486898

Submitted on 20 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Inhibitory checkpoint receptors control CD8+ resident memory T cells to prevent skin allergy 3

- 4
- 5 Pia Gamradt PhD^{1-5*}, Léo Laoubi MSc^{1-5*}, Audrey Nosbaum MD/PhD¹⁻⁵, Virginie
- 6 Mutez MSc¹⁻⁵, Vanina Lenief MSc¹⁻⁵, Sophie Grande MD⁶, Daniel Redoulès PhD⁷,
- 7 Anne-Marie Schmitt MD/PhD⁸, Jean-François Nicolas MD/PhD¹⁻⁶ and Marc
- 8 Vocanson PhD¹⁻⁵
- 9

10 Affiliations:

- ¹ CIRI, International Center for Infectiology Research, Université de Lyon, Lyon,
- 12 France.
- 13 ² INSERM, U1111, Lyon, France.
- ³ Ecole Normale Supérieure de Lyon, Lyon, France.
- ⁴ Université Lyon 1, Centre International de Recherche en Infectiologie, Lyon, France.
- ⁵ CNRS, UMR 5308, Lyon, France.
- ⁶Allergology & Clinical Immunology, CH Lyon-Sud, Pierre-Benite, France.
- 18 ⁷ Pierre Fabre R&D Dermocosmétique, Toulouse, France
- ⁸ Pierre Fabre R&D Pharmaceuticals, Toulouse, France

20 * Equal contributors

- 21
- 22

23 Correspondence:

- 24 Marc Vocanson, CIRI-INSERM U1111, 21 avenue Tony Garnier 69007 Lyon, France
- 25 Tel:+33 437 28 23 48; e-mail address: marc.vocanson@inserm.fr
- 26
- 27 **Running title**: CD8+ Trm in skin allergy.
- 28
- 29 **Conflict of Interest**: The authors declare no competing financial interests. DR and
- 30 AMS are employed by Pierre Fabre. All other authors are public employees from
- 31 INSERM, University and Lyon-Sud hospital.
- 32
- 33 Word count= 3739 words
- 34 **Figure count=** 6 figures

35

36 Abbreviations

- 37 ACD: Allergic contact dermatitis
- 38 Ag: Antigen
- 39 DC: Dendritic cells
- 40 DNFB: 2,4-dinitrofluorobenzene
- 41 DNP: Dinitrophenyl
- 42 dLN: Draining lymph node
- 43 DT: Diphtheria toxin
- 44 iDTR: Inducible diphtheria toxin receptor
- 45 IFN-γ: Interferon gamma
- 46 CHS: Contact hypersensitivity
- 47 ICR: Inhibitory checkpoint receptor
- 48 OXA: Oxazolone
- 49 Tcm: Central memory T cell
- 50 Tem: Effector memory T cell
- 51 Trm: Resident memory T cell

- 53 Abstract
- 54

55 <u>Background:</u> Tissue-resident memory T cells (Trm) are detrimental in 56 numerous chronic inflammatory diseases, including allergic contact dermatitis (ACD).

57 <u>Objectives:</u> To analyze the contribution of Trm to the chronicity and severity of 58 ACD and to define the local parameters regulating their development and functions.

59 <u>Methods:</u> We used an experimental model of ACD, i.e. contact 60 hypersensitivity (CHS) to 2,4-dinitrofluorobenzene (DNFB) which is mediated by 61 CD8+T cells.

Results: Our data show that early effector T cells accumulated in the skin 62 63 during the acute CHS reaction and gave rise to epidermal CD8+ Trm expressing a specific set of immune checkpoint receptors (ICR), such as PD-1 and Tim-3. Those 64 65 Trm remained in the epidermis for several weeks and mediated the eczema exacerbations, which developed upon allergen re-exposure without the contribution 66 67 of circulating specific T cells. Furthermore, allergen-induced Trm reactivation was constrained, since treatment with ICR antagonists dramatically enhanced the 68 69 magnitude and severity of eczema exacerbations. Finally, we show that the 70 persistence of the allergen in the epidermis for long periods of time was responsible 71 for both the development and maintenance of epidermal Trm as well as the sustained 72 expression of ICR.

<u>Conclusion:</u> Although CD8+Trm cells are key for the pathophysiology of ACD,
 intrinsic mechanisms control their reactivation to prevent damaging immunopathology.
 Developing strategies targeting the reactivation of skin Trm *in situ* via their ICR
 should open new perspectives for the treatment of ACD.

- 77
- 78
- 79

Keywords: Resident memory T cells (Trm); eczemas; allergic contact dermatitis;
inhibitory check point receptors; immunopathology.

- 82
- 83
- 84
- 85

86 Key Messages

87

High numbers of hapten-specific CD8+ Trm accumulate at the sites of healed
 eczema lesions in response to the long-term persistence of hapten moieties in the
 skin.

•CD8+ Trm are key for the chronicity, severity and recurrence of the pathology.

However, they express several inhibitory receptors, such as PD-1 or TIM-3,
which keep them in check to preserve skin integrity and to avoid the development of
severe immunopathology.

95 **Capsule summary**

The present study confirms the crucial role of epidermal CD8+ Trm for the recurrences of allergic contact dermatitis and highlights the contribution of immune checkpoint receptors on CD8+ Trm to prevent eczema flares upon allergen exposure.

- 101 Introduction
- 102

103 Resident memory T cells (Trm), which are classically identified by their stable 104 expression of CD69 and CD103 ¹⁻⁴, constitute a recently described subset of memory 105 T cells that do not re-circulate throughout the organism. They persist long-term within 106 peripheral tissues and organs, where they organize an optimal front-line defense 107 against invading pathogens or neoplastic cells ^{1, 5, 6, 7, 8}.

108 Beyond their demonstrated active contribution to host protection, there is an 109 Trm also emerging understanding that participate in several autoimmune/inflammatory diseases, in which they can instigate or augment the 110 immunopathology ^{9,10}. Trm have been described in different skin diseases such as 111 psoriasis, vitiligo ³, fixed drug eruption ¹¹ or leukemic cutaneous T cell lymphoma ^{12,} 112 13 113

114 Allergic contact dermatitis (ACD) is a common chronic and relapsing T cell-115 mediated allergic skin disease. ACD expresses as eczema flares (also referred to as 116 exacerbations), which consist in the worsening of the skin inflammation upon allergen 117 exposure. Exacerbations usually develop on the same body sites, i.e. on previously affected but healed skin¹⁴. This observation has led to the concept of "local memory" 118 119 to allergens", postulating that specific T lymphocytes (i) persist for several months in 120 previous sites of eczema and, (ii) are important in flare-up reactivity and in chronic inflammation ^{14, 15}. Recent works have shown that skin Trm are responsible for the 121 development of these early and intense ACD flares ¹⁶⁻¹⁸. However, little is known 122 regarding the functional phenotype of Trm, their long term persistence, the antigen 123 124 requirement for their development and survival, or the mechanisms which control 125 their reactivation upon allergen exposure.

126 In this study, using the experimental model of contact hypersensitivity (CHS) 127 to the chemical allergen 2,4-dinitrofluorobenzene (DNFB) ¹⁹, we confirm the crucial 128 role of epidermal CD8+ Trm in eczema exacerbations and we precisely define their 129 phenotype and specificity. More importantly, we demonstrate that intrinsic cell 130 mechanisms, i.e. the expression of inhibitory checkpoint receptors, prevent their 131 uncontrolled reactivation to avoid eczema flares upon allergen exposure.

132 Methods:

133

A brief description of the Methods is provided below. See additional details in theSupplemental Methods section.

136

137 Animals and reagents

Mice, allergens (2,4-dinitrofluorobenzene [DNFB], 2,4-dinitrobenzenesulfonic acid
[DNBS], or oxazolone) or mAbs used in this study are reported in the Supplementary
Method section.

141

142 Contact hypersensitivity to DNFB and flare-up reactions

For most experiments, CHS was induced as previously described ²⁰. Briefly, animals 143 were sensitized epicutanously on the shaved abdomen with 25µl of 0.5% DNFB on 144 145 day -5, and were challenged on the left ear on day 0 with 2x5µl 0.13% DNFB while 146 the right ear received the acetone/olive oil vehicule. Allergic animals were next 147 retested at day 30, or months 3, 6 and 12, with different doses (0.01, 0.05 and/or 148 0.13%) of DNFB or with 1% OXA, both on healed (left ear) and/or naïve (right ear) 149 skin, as indicated. 150 In some experiments, DNFB-allergic C57BL/6 or reconstituted CD3*ɛ*-/- mice were

depleted of circulating or of skin CD8+ T cells by anti-CD8 mAbs or diphtheria toxin
(DT) injections, and treated with anti-PD-1 (RMP1-14, 200µg/ml), anti-TIM-3 (RMT323, 200µg/ml) or respective IgG2a isotype (2A3, 400 µg/ml) (all from BioXCell, West
Lebanon, USA) at indicated time points.

155 Results

156

Allergen-specific CD8+ Trm persist for months within the epidermis and dermis of healed CHS lesions

159 In this study, we used DNFB allergic mice, which were sensitized (day-5) on 160 the abdomen and challenged 5 days later (day 0) on the left ear with DNFB, leading 161 to a CHS reaction peaking at day 2 and resolving by day 15 (Fig.1A). DNFB allergic 162 mice were then analyzed at different time points after the resolution of CHS (day 30, 163 months 2, 6 and 12) for the presence of Trm, as well as for their functional properties. 164 In this model, the left ear, which received DNFB at day 0 and developed a CHS 165 response at day 2 is called the "healed skin", whereas the right ear which received 166 the vehicule and did not develop CHS is called the "naive skin". At day 30 and 167 thereafter, naïve and healed skin look identical without any clinical or histological sign 168 of inflammation.

To confirm that Trm persist at the sites of CHS skin inflammation ^{16, 17, 18}. 169 healed and naive skin of DNFB-allergic mice were first collected at day 30 and 170 171 processed for the presence of CD8+ and/or CD4+ T cell subsets by FACS and 172 immunofluorescence microscopy. While the epidermis and the dermis of naive skin 173 were nearly exclusively seeded with CD4+ T cells, increased numbers of CD8+ T 174 cells were recorded in healed CHS lesions (Fig.1B and Fig.S1). Approximately 70% 175 of epidermal and dermal CD8+ T cells co-expressed the two canonical Trm markers CD103 and CD69²¹, emphasizing the residency properties of these cells (hereafter 176 177 referred to as Trm) (Fig.1C).

178 Time course experiments next demonstrated that CD8+Trm progressively 179 accumulated in the epidermis during the resolution of acute CHS inflammation, with a 180 gradual increase between day 2 and day 15 post DNFB challenge (Fig.S2A). Trm 181 numbers then stabilized between days 15 and 30, along with complete resolution of 182 the skin inflammation, before they underwent a progressive and profound attrition up 183 to 12 months post challenge (Fig.1D). Of note, depletion of circulating, but not of 184 skin-resident CD8+ T cells by anti-CD8+ mAb treatment at day 2 post challenge, did 185 not change the numbers of epidermal Trm recorded in the skin (Fig.S2B&C), 186 indicating that skin Trm mainly derive from *in situ* proliferation of early effector cells 187 present at the peak of the CHS response (Fig.S2D).

188

To determine the proportion of allergen-specific Trm among CD8+ Trm

present in the healed lesion of DNFB-allergic mice, skin CD8+ and CD4+ T cell 189 190 subsets were subsequently collected at 30 days, FACS sorted and re-activated ex-191 vivo with allergen-pulsed bone marrow-derived dendritic cells (BMDCs). The 192 following day, the number of spot forming cells (SFCs) producing IFN-γ, IL-17a or IL-193 4 was determined by enzyme-linked immunospot (ELISpot) assay. While approx. 1% 194 of epidermal and 0.2% of dermal CD8+ T cells of healed CHS lesions were antigen-195 specific and produced IFN-γ (Fig.1E), IL-17a- or IL-4- were not detected (data not 196 shown). Comparatively, the frequency of DNFB-specific cells among total CD8+ T 197 cells from dLNs, which comprise a mix of effector (Tem) and central (Tcm) memory T 198 cells and dLN Trm, was <0.1%.

199 Time course experiments revealed a progressive and significant reduction in 200 the numbers of DNFB-specific cells during the months following DNFB challenge, 201 with an approx. 10 fold decrease at month 12, when compared to day 30 (Fig.1F).

202 Thus, these data show that healed CHS lesions are enriched for allergen-203 specific CD8+ Trm which persist in the skin for months.

- 204
- 205

CD8+ Trm mediate DNFB-induced flare-up reactions

206 We next examined the contribution of CD8+ Trm to the allergen-induced 207 eczema flares. When DNFB-allergic animals were re-challenged on the healed skin 208 at day 30 with a standard dose of 0.13%, they developed potent flare-up reactions, 209 with a more severe magnitude than the response induced on naive skin and the 210 background response induced in non-allergic animals (Fig.2A, left part). The flare-211 up CHS reactions were antigen-specific, since application of the irrelevant strong 212 allergen oxazolone (OXA) on the healed or naive skin of DNFB-allergic animals 213 triggered only background responses of similar magnitude to the one induced in non-214 allergic animals (Fig.2A, right part).

215 To demonstrate the contribution of DNFB-specific CD8+ Trm to the 216 exaggerated reaction recorded in healed lesions upon allergen-retest, we developed 217 an original inducible diphtheria toxin receptor (iDTR)-based approach, using DNFB-218 allergic CD3*ɛ*-/- lymphopenic recipient mice, reconstituted prior to the induction of 219 DNFB-CHS with iDTR-CD8+ and WT-CD4+ T cells collected by FACS sorting from 220 iDTR/CD4cre and C57BL/6 donor mice, respectively. Flare-up reactions upon retest 221 were completely abrogated in recipient mice injected with diphtheria toxin (DT) (one

day before re-challenge), while untreated or anti-CD8 mAb treated control mice
developed a full flare-up response (Fig.2B). Conversely to anti-CD8b mAb treatment
which only depletes circulating CD8+ T cells, DT injection depleted all the circulating
and skin CD8+ T cells, while sparing non-CD8+ T cells in these recipients (Fig.S3).

226 Our results thus show that antigen-specific CD8+ Trm are of prime importance 227 for the development of recurrent flare-up reactions recorded on healed lesions of 228 DNFB-allergic mice.

229

230

0 **CD8+** Trm are hypo-responsive to low DNFB doses

231 We next examined flare-up reactions induced in allergic animals by low DNFB 232 doses, i.e. below the standard dose of 0.13%. As expected, repeated applications of 233 low DNFB doses on healed skin induced an intense flare-up reaction. It required 3 234 consecutive administrations of DNFB 0.05% (on days 0, 2, and 6) to generate flares 235 of similar magnitude to the one provoked by a single optimal dose (Fig.3A). By 236 contrast, 6 consecutive administrations (on days 0, 2, 6, 8, 13, and 15) of DNFB 237 0.01% failed to induce a flare-up reaction. On naive skin, 6 consecutive 238 administrations of DNFB 0.05% (on days 0, 2, 6, 8, 13 and 15) did not induce 239 significant flares (data not shown). These data indicate that, although specific Trm 240 are seeded in the skin at significant density, they are actively restrained to prevent excessive immunoreactivity in response to DNFB application below a certain 241 242 threshold (Fig.3A).

243

244 Epidermal CD8+ Trm express a restricted set of inhibitory check point 245 receptors

246 In this respect, we investigated the expression of different inhibitory checkpoint receptors (ICRs) by skin CD8+ Trm²². We noticed that these cells expressed high 247 levels of PD-1²³, TIM-3²⁴ or 2B4²⁵ Fig.3B), as well as CD5²⁶, but not TIGIT²⁷, 248 LAG-3, CTLA-4²⁸ (Fig.S4), compared to CD8+ Tem and Tcm or naïve CD8+ T cells 249 isolated from the dLNs of DNFB-allergic mice. CD160 and BTLA ²⁹ were also not 250 observed on skin CD8+ Trm, while VISTA ³⁰ was detected at a low level ((Fig.S4). 251 252 Further analysis showed that approx. 55% of CD8+ Trm expressed PD-1 (Fig.3C, 253 top). In both the PD-1+ and PD-1- subpopulations, a majority of the cells co-254 expressed TIM-3 and 2B4 [Fig.3C, bottom].

Time course analysis revealed a rather constant PD-1 expression on CD8+ Trm from days 2 to 15 post DNFB challenge (approx. 80%), associated with a progressive decline in the following months (approx. 20% at month 12). By comparison, the percentage of TIM3+ cells remained stable throughout the protocol (approx. 80%), while the percentage of 2B4+ cells increased dramatically from around 10% at day 4 to almost 80% from day 30 to month 12 (**Fig.3D**).

Of note, the number of DNFB-specific IFN-γ-producing T cells among
CD8+PD1+ Trm was two times higher compared to their PD1- counterparts, as
revealed by ELISpot assay at day 30 post DNFB challenge (Fig.S5).

264

265 Blocking ICR signaling leads to severe CHS responses upon challenge with 266 Iow DNFB doses

267 We then tested for the functional relevance of ICRs expressed on skin Trm, 268 and their ability to prevent eczema exacerbation. Blocking ICR in vitro using anti-PD-269 1 and anti-TIM-3 mAbs increased the reactivity of purified epidermal CD8+ Trm and 270 their capacity to produce IFN- γ (Fig.4A) and Granzyme-B (data not shown) upon ex 271 vivo re-activation with allergen-pulsed BMDCs. Of note, the impact of blocked TIM-3 272 signaling was more modest than for PD-1, with an increase of approx. 40% and 273 160% regarding the number of IFN- γ -producing cells, respectively. More importantly, 274 in vivo blockade of these two ICRs triggered severe flare-up CHS reactions, when 275 DNFB-allergic animals (depleted of all circulating CD8+ T cells by anti-CD8 mAb 276 treatment just before re-challenge) were repeatedly re-exposed to low DNFB doses 277 (0.05%), which induced only a very mild inflammation in untreated animals (Fig.4B). 278 Of note, the acute depletion of skin CD8+ Trm by DT injection using our iDTR-based 279 model, abrogated the development of the CHS reaction induced by anti-PD-1 and 280 anti-TIM-3 blockade (Fig.S6).

Taken together, our results show that PD-1 and, to a lesser extent, TIM-3, control the reactivation of epidermal CD8+ Trm and prevent the development of CHS responses when individuals are re-exposed to low allergen doses.

284

285 Allergen persists for several weeks within the epidermis

To better understand why CD8+ Trm are restrained in the skin and maintain ICR expression for weeks, we first investigated how long DNFB, which is administrated epicutaneously, persists inside the tissue. Indeed, sustained
 expression of ICRs has previously been associated with recent or chronic stimulation
 of T cells by their cognate Ag²².

Using standard immunofluorescence staining of DNP-moieties generated at different time points after DNFB painting and light sheet fluorescence microscopy (LSFM), we observed that around 40% of the epidermal compartment was stained by anti-DNP mAbs at day 2 post challenge. Interestingly, approx. 10% was still stained at days 8 and 15 and about 5% remained labeled at day 30 post challenge, with a pronounced accumulation of CD8+ T cells (detected by using anti-CD8b mAb staining) around DNP-stained areas (**Fig.5** and **movies S1-S6**).

298 Our results thus revealed an underestimated persistence of chemical allergen-299 moieties in the skin, for at least one month.

300

Allergen persistence amplifies the number of CD8+ Trm and modulates their ICR phenotype

303 To determine whether the long-term persistence of the allergen impacted the 304 ICR expression on skin Trm, we compared cells generated via the application of the cognate Ag (DNFB) or via a prime and pull strategy ³¹. The latter allows recruiting Ag-305 306 specific T cells into the skin in an antigen-independent manner, via the application of 307 an inflammatory but structurally irrelevant molecule. Here, we used the strong 308 contact allergen OXA. In addition, to track specific CD8+ Trm, we developed a new 309 CHS model based on the use of a MHC class I-restricted ovalbumin peptide bearing a dinitrophenyl (DNP)-moiety (DNP-peptide)³², which displays similar features to its 310 311 DNFB counterpart, but in which specific CD8+ T cells can be detected using 312 fluorescently labeled dextramers loaded with the cognate DNP-peptide (Fig.S7).

313 Using the prime and pull strategy, the absence of cognate antigen in the skin 314 should lead to (i) a significant decrease of CD8+ Trm numbers, as previously reported ³³⁻³⁵, (ii) a modulation of their ICR phenotype due to the lack of TCR 315 316 stimulation. Hence, while we observed that similar numbers of specific CD8+ T cells 317 were recruited into the epidermis 2 days after the challenge with DNP-peptide or OXA, only $1/_4$ of the number of epidermal specific CD8+ Trm induced by cognate Ag 318 319 challenge was detected 40 days after OXA challenge (Fig.6A). Moreover, 320 significantly less TIM-3 but not PD-1 expression was detected on dextramer+ CD8+ T cells at day 2 post OXA versus DNP challenge, indicated by a drop in the GMFI from approx. 3000 to 2200 (**Fig.6B-C**). At day 40 post challenge, the expression of both PD-1 and TIM-3 was decreased (**Fig.6B-C**). Conversely, we did not observe any difference in the expression of 2B4 between the two recruitment strategies (**Fig.6B-C**).

Therefore, long term persistence of the allergen in the skin not only amplifies the number of specific CD8+ Trm that populate the epidermis, but also partially modulates their phenotype.

329 Discussion

330

Tissue-resident memory T cells are considered detrimental in numerous 331 332 human inflammatory diseases, including skin allergies. In the present study, we 333 capitalized on a reference mouse model of ACD to study the local parameters 334 regulating Trm development and functions during pathological processes. We report 335 that, in allergic animals, the sites of previously inflamed skin are seeded with a high 336 frequency of specific CD8+ Trm, in both the epidermis and the dermis. These cells 337 are instrumental for the recurrence and severity of eczema, since they are sufficient 338 to evoke intense flare-up reactions upon allergen challenge, without help from their 339 circulating counterparts. However, albeit they are highly pathogenic, specific CD8+ 340 Trm display certain levels of hypo-responsiveness. They express a specific pattern of 341 inhibitory receptors such as PD-1 and TIM-3 (but also high levels of 2B4 and CD5), 342 which attenuate their reactivity and prevent excessive responses when individuals 343 are re-exposed to the allergen. Finally, a major observation was the underestimated 344 long-term persistence of the allergen inside the epidermis, which drives the 345 expansion of early CD8+ T cell effectors and their differentiation into Trm, but which 346 also modulates their ICR expression to keep them in check. Our results therefore 347 identify intrinsic factors that control pathogenic Trm to preserve skin integrity and to 348 avoid the development of chronic and severe immunopathology.

- 349
- 350

CD8+Trm are major drivers of the chronicity and severity of eczema.

In this study, allergic skin responses were triggered by the epicutaneous application of DNFB, a chemical allergen/hapten endowed with strong sensitizing properties. We observed that the majority of local memory cells which populated the epidermis and dermis of previously affected skin were CD8+ Trm. We failed to detect allergen-specific CD4+ T cells producing IFN- γ , IL-4, and IL-17.

We demonstrated that epidermal CD8+ Trm are sufficient to prompt severe eczema exacerbations, which in consequence categorize them as prominent drivers of the chronicity and severity of eczema. The concept of local skin memory, to explain the strong and accelerated allergen-induced inflammatory reaction at the site of previously affected skin, was introduced more than three decades ago by Scheper et al. ¹⁵. So far, major but only indirect demonstrations have suggested that skin Trm, and notably CD8+Trm, are responsible for the development of these early and

intense flares ¹⁴⁻¹⁷. The most solid evidence came from the study by Gaide et al., 363 364 which reported that flare-up reactions are not prevented when allergic animals are injected with drug compounds that block the egress of memory T cells from the 365 lymphoid organs ¹⁶. In the present study, the sharp elimination of iDTR+ CD8+ Trm 366 367 from the skin and the subsequent abrogation of allergen-induced flares firmly 368 demonstrated the contribution of Trm to the allergen-induced exacerbations, excluding the potential involvement of other tissue resident cells such as dermal ILCs 369 or liver NK memory cells ³⁶⁻³⁸. Besides, the fact that the application of the irrelevant 370 371 allergen OXA gave similar inflammation on healed and naive skin in DNFB-allergic 372 mice, enabled us to exclude the possibility that the intense flares recorded at the 373 sites of healed lesions were due to bystander activation of non-allergen-specific Trm, 374 solely as the results of the inflammatory environment and cytokine signaling on CD8+ Trm ³⁹⁻⁴¹. 375

376

377 The long-term persistence of chemical allergen-moieties in the skin promotes 378 the formation of CD8+ Trm.

379 The mechanisms that drive the formation and fate of skin Trm are complex 380 and so far only partially understood. Here, we observed that the accumulation of 381 epidermal CD8+ Trm correlated with the long-term persistence of the allergen in the 382 skin (at least > than 30 days), with a progressive decline from day 0 to day 30. Of 383 note, the allergen persistence at day 30 was mainly observed in keratinocytes from 384 hair follicles. Since epidermal renewal needs only 8-10 days in mice, this observation 385 strongly suggests that the allergen is stocked in long-lived slow-cycling epidermal 386 stem cells, which represent a small fraction of interfollicular epidermis and hair 387 follicles ⁴²⁻⁴⁴. Hence, one could speculate that, mimicking viral immunity controlling viruses integrated in our genomes ⁴⁵, allergen-specific CD8+Trm are placed here to 388 389 survey long-lived skin cells that continuously present allergen-epitopes. It will be 390 crucial to determine exactly how long an allergen can persist in the skin, and whether 391 its presence is functional and prompts Trm activation and/or survival, avoiding 392 progressive attrition of specific Trm pools from the epidermis (as shown in Fig.1F). 393 Here, confirming previous studies, we demonstrated that while a significant number 394 of allergen-specific Trm can be recruited to the skin upon prime and pull strategy, this 395 number is dramatically amplified when cells recognize their cognate Ag in the skin^{33,} 46 396

397

398

CD8+ Trm are placed at the skin interface, but they are kept in check.

399 The most striking finding of our study was certainly the demonstration that, 400 despite their key role in the recurrence of the pathology, allergen-specific CD8+ Trm 401 are tightly regulated, and express ICRs, which prevent them from unnecessary 402 strong reactivation upon allergen exposure. Several investigators have previously 403 reported the expression of different inhibitory molecules by CD8+ Trm, not only in cancer ^{47,48}, but also in viral infections ⁴⁹⁻⁵², autoimmune uveoretinitis ⁵³ or at 404 homeostasis ^{54, 55}. Besides, recent comparison of the gene-expression pattern of lung 405 406 Trm versus circulating Tem in humans demonstrated that Trm expressed a 407 restrained genetic program with high expression of CTLA4, BTLA, LAG3, SPRY1, A2AR, PD-1, TWIST1, BACH2 genes ⁵⁵. Here, we reported that allergen-induced 408 409 Trm expressed at their surface different levels of a restricted set of ICRs (PD-1, TIM-410 3, 2B4, but also a high level of CD5, a low level of VISTA, but not of TIGIT, BTLA, 411 LAG-3, CD160 or CTLA-4), corroborating the hypothesis that the reactivation of Trm 412 must be tightly controlled to ensure sufficient but limited reactivity. Interestingly, a 413 previous study demonstrated that the pattern of ICR coexpression and the number of 414 receptors simultaneously expressed by the same CD8+ Trm affect the magnitude of the restraint on the Trm ²². In this study, we observed that the pattern of ICR co-415 expression varies over time, with progressive increase of 2B4, compared to PD-1 or 416 417 and TIM-3, during the first month post DNFB challenge, and late decline of PD-1, but 418 not of TIM-3 or 2B4 expression, after 6-12 months. Our results then guestion about 419 the environmental signals that participate in modulating the level of ICR expression 420 and thereby the functions of skin Trm. It was recently suggested that the acquisition 421 of a specific inhibitory program could be associated to the affinity/avidity of the initial TCR-pMHC interactions between Trm precursors and antigen presenting cells ⁵¹. 422 423 Here, we showed that the persisting allergen in the skin not only amplified the 424 number of CD8+ Trm populating the epidermis, but also maintained PD-1 and TIM-3 425 expression, which is reminiscent of a recent work describing the presence of clonally 426 expanded Trm-like PD1+CD8+ cells in the synovial fluid of patients suffering from chronic juvenile idiopathic arthritis ⁵⁶. However, beyond the antigen persistence, it will 427 be interesting to determine whether hair follicle-derived IL-15 or IL-7 cytokines ⁵⁷, or 428 TGF- β ⁵⁸, which were reported to be instrumental for Trm differentiation, are also 429 430 susceptible to modulate the ICR program on skin Trm; the more so since we have observed that these three cytokines are synthesized during the resolution of the
DNFB inflammation (data not shown). Finally, it will also be important to determine
the respective role of epidermal Langerhans cells, dendritic epidermal T cells
(DETCs), T regulatory cells or innate lymphoid cells... in the control of Trm
reactivation via ICR acquisition and/or ligation.

In conclusion, our results provide important information for considering the unique nature of allergen-induced CD8+ Trm and the mechanisms that preserve their unwanted reactivation and the subsequent development of chronic or severe skin allergy. The development of strategies targeting the reactivation of skin Trm *in situ* via their ICRs should open new avenues to treat ACD.

441 **Author contributions**

- 442 PG, LL, VM, VL and PR carried out the experiments and analysed the data.
- 443 AN, SG, DR, AMS participated in the interpretation of the data.
- 444 JFN and MV designed the experiments and supervised this study.
- 445 PG, JFN and MV wrote the manuscript.
- 446 All authors had final approval of the submitted and published version.
- 447

448 Acknowledgements

- 449 We thank T. Andrieu, S. Dussurgey and C. Chamot (Plateaux techniques de
- 450 cytométrie en flux et d'imagerie/microscopie, US8 / UMS3444 BioSciencesGerland -
- 451 Lyon Sud), as well as D. Resnikoff (Centre d'Imagerie Quantitative Lyon-Est) for their
- 452 assistance with flow cytometry and microcospy.
- 453 This study was supported by Pierre Fabre.

- 455 **Figure legends**
- 456

Figure 1: Allergen-specific CD8+ Trm persist long-term in the epidermis and
dermis of healed CHS lesions

459 A. Protocol: CHS response to DNFB to track the persistence and function of DNFB-460 specific Trm.

B. Quantification of skin T cell subsets. Histograms depict mean cell numbers ±
SEM of CD8+ and CD4+ T cell subsets present in the epidermis or dermis of healed
and naive skin, at day 30 post challenge, as determined by FACS analysis.

464 **C. Canonical Trm marker expression.** FACS plots and histograms depict mean 465 percentages ± SEM of CD8b+CD103+CD69+ T cells among CD45+ cells present in 466 the epidermis and dermis of healed skin, or in dLNs, at day 30.

467 **D. Long-term persistence of skin Trm.** The mean numbers ± SEM of CD8+ 468 CD103+CD69+ Trm was also assessed at months 3, 6 and 12.

469 E&F. DNFB-specific T cell responses. Mean number of DNFB-specific CD8+ or

470 CD4+ T cells (± SEM) determined by IFN-γ-ELISpot at day 30 (E). The persistence in

471 the epidermis of IFN-γ-producing DNFB-specific cells was also analyzed at months 3,
472 6 and 12 (F).

- 473 All results are representative of two or three independent experiments with 4-10 mice474 per group.
- 475 n.s.=not significant, *P<0.05, **P<0.01,***P<0.001, ****P<0.0001. One-way ANOVA
 476 or Mann-Whitney U test.
- 477

478 Figure 2: Skin CD8+ Trm mediate site- and Ag-specific flare-up reactions in
479 DNFB-allergic mice.

480 **A. CHS response of DNFB-allergic mice to DNFB or OXA.** DNFB-allergic C57BL/6 481 mice were re-challenged with DNFB or oxazolone (OXA) on healed skin lesions or 482 naive skin at day 30. As control, DNFB and OXA were applied on the ears of naïve 483 mice. The following day, CHS reaction was determined by measuring the mean ear 484 oedema (μ m) ±SEM.

B. Depletion of skin CD8+ Trm abrogates CHS response to DNFB. CHS to DNFB
was induced in CD3*E*-/- mice reconstituted with iDTR-CD8+ and WT-CD4+ T cells. At
day 30 and 60 and 1 day after DT or anti-CD8 mAb i.p. injections, mice were re-

- 488 challenged with DNFB. The following day, CHS reaction was determined by 489 measuring the mean ear oedema (μ m) ±SEM.
- All results are representative of two or three independent experiments with 4-5 miceper group.
- 492 n.s.=not significant, *P<0.05, **P<0.01,***P<0.001, ****P<0.0001. One-way ANOVA.
 493
- 494 Figure 3: Epidermal CD8+ Trm, but not circulating memory CD8+T cells, 495 express several inhibitory checkpoint receptors (ICR).
- 496 **A. CHS response to repeated applications of low DNFB doses.** DNFB-allergic 497 C57BL/6 mice were re-challenged (arrows) with low DNFB doses (0.05% at days 0, 2, 498 and 6; or 0.01% at days 0, 2, 6, 8, 13, and 15) or with a single standard DNFB dose 499 (0.13% at day 0). CHS reaction was determined by measuring the mean ear oedema 500 (μ m) ±SEM.
- 501 **B. ICR expression by epidermal or dLN CD8+ memory T cell subsets.** FACS 502 plots depict representative PD-1, TIM-3 or 2B4 expression by epidermal CD8+ Trm 503 and dLN CD8+ Tem, Tcm or naïve cells, at day 30 post DNFB challenge.
- 504 C. ICR co-expression by CD8+ Trm. Mean percentages ±SD of TIM-3 and 2B4 co 505 expression on gated epidermal PD-1+ and PD-1- CD8+ Trm subsets, at day 30.
 506 Dendritic epidermal T cells (DETCs) are shown as control.
- 507 **D. ICR expression by epidermal CD8+ T cells during the course of CHS** 508 **response to DNFB and after its resolution.** Mean percentages ±SD of PD-1+, TIM-509 3+ and 2B4+ cells among epidermal CD8+ Trm from day 2 to month 12.
- 510 All results are representative of two or three independent experiments with 4-5 mice
- 511 per group or time point.
- 512 *P<0.05. One-way ANOVA.
- 513

514 Figure 4: Blocking ICR signaling increases the reactivity of CD8+ T cells *in* 515 *vitro* and exacerbates the flare-up CHS reactions *in vivo*.

516 **A. DNFB-specific T cell responses in the presence of ICR blocking mAbs.** CD8+ 517 T cells from healed epidermis were co-cultured overnight with haptenized (DNBS; 518 0.4mM) or non-haptenized (NH) BMDCs in the presence of anti-PD-1 and/or anti-519 TIM-3 mAb. IgG2a was added to control co-cultures. The following day, the number 520 of specific T cells was determined by IFN- γ ELISpot. Results are expressed as the 521 mean number of SFC/10⁶ CD8+ T cells ± SEM. **B ICR antagonists increase CHS responses to low DNFB doses.** DNFB-allergic mice were re-challenged with low DNFB doses (0.05%, at days 30, 32, 34), while ICR blockade was maintained by i.p. injection of anti-PD-1 and anti-TIM-3 mAbs at days 26, 28, 30 and 32. As control, DNFB-allergic mice were injected with IgG2a mAbs. Circulating CD8+ T cells were depleted by i.p. injection of anti-CD8 mAbs at day 27. CHS reaction was determined by measuring the mean ear oedema (μ m) ± SEM.

- 529 All results are representative of three independent experiments with 5-15 mice per 530 group.
- 531 n.s.=not significant, *P<0.05, **P<0.01. Mann-Whitney U test.
- 532

533 Figure 5: Allergen persistence in the skin after the resolution of CHS to DNFB.

534 Illustrative and quantitative analysis of DNP moieties present in the skin during the 535 course of CHS to DNFB.

- 536 **A.** Threshold segmentation images. Epidermal sheets collected before and 2, 8, 537 15 or 30 days after DNFB challenge of DNFB-sensitized animals were explored for 538 the presence of DNP moieties (green), CD8b+ T cells (red), and DETCs (yellow) by 539 standard immunofluorescence staining. Representative photographs acquired on a 540 Lightsheet Z.1 microscope after threshold segmentation using Bitplane Imaris are 541 shown. Control isotype staining was performed on epidermal sheets collected at day 542 8. White arrows highlight the pronounced accumulation of CD8+ T cells around DNP-543 stained areas.
- **B. Quantification.** The percentage of epidermal area stained by anti-DNP mAbs was calculated throughout the CHS response to DNFB by determining the total epidermal area (μ m³) analyzed by DAPI nuclear staining and the DNP-stained area (μ m³). For each individual mouse 3-4 pictures were analyzed.
- 548 All results are representative of two independent experiments with 3 mice per time 549 point.
- 550

Figure 6: Accumulation of epidermal Trm and maintenance of ICR expression is antigen-dependant

553 Naïve C57BL/6 mice were immunized i.p. with DNP-peptide pulsed-BMDCs and 554 challenged 5 days later on the left ear with the DNP-peptide in DMSO or with an 555 irrelevant hapten, oxazolone (OXA). 556 The number of DNP-peptide specific CD8+ T cells recruited in the epidermis via the 557 Ag-specific or the non Ag-specific approach ("prime and pull strategy") was 558 measured by FACS at days 2 and 40, using fluorescently labeled dextramers loaded 559 with the respective DNP-peptide (**A**). Results are depicted as mean values 560 (percentage) ±SEM.

561 The expression levels of PD-1, TIM-3, and 2B4 by DNP-specific CD8+ Trm after Ag-

562 specific (DNP-peptide) or non Ag-specific (Oxazolone) recruitment was assessed.

563 Representative histograms (day 40) (B) and mean values of respective geometric

- 564 mean fluorescence intensity (GMFI, days 2 and 40) ±SEM (**C**) are shown.
- All the results are representative of three independent experiments with 4-5 mice pergroup.

567 n.s.=not significant, *P<0.05, **P<0.01. One-way ANOVA.

- 569 **References**
- 570
- 5711.Ariotti S, Hogenbirk MA, Dijkgraaf FE, Visser LL, Hoekstra ME, Song JY, et al. T cell572memory. Skin-resident memory CD8(+) T cells trigger a state of tissue-wide573pathogen alert. Science 2014; 346:101-5.
- 574 2. Bergsbaken T, Bevan MJ. Proinflammatory microenvironments within the
 575 intestine regulate the differentiation of tissue-resident CD8(+) T cells responding
 576 to infection. Nat Immunol 2015; 16:406-14.
- Cheuk S, Schlums H, Gallais Serezal I, Martini E, Chiang SC, Marquardt N, et al.
 CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic
 Function in Human Skin. Immunity 2017; 46:287-300.
- 580 4. Naik S, Bouladoux N, Linehan JL, Han SJ, Harrison OJ, Wilhelm C, et al.
 581 Commensal-dendritic-cell interaction specifies a unique protective skin immune
 582 signature. Nature 2015; 520:104-8.
- 5835.Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T584cells in nonlymphoid tissue that provide enhanced local immunity during585infection with herpes simplex virus. Nat Immunol 2009; 10:524-30.
- 586 6. Steinert EM, Schenkel JM, Fraser KA, Beura LK, Manlove LS, Igyarto BZ, et al.
 587 Quantifying Memory CD8 T Cells Reveals Regionalization of Immunosurveillance.
 588 Cell 2015; 161:737-49.
- Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC, Kupper TS. Skin infection
 generates non-migratory memory CD8+ T(RM) cells providing global skin
 immunity. Nature 2012; 483:227-31.
- 5928.Schenkel JM, Fraser KA, Vezys V, Masopust D. Sensing and alarm function of593resident memory CD8(+) T cells. Nat Immunol 2013; 14:509-13.
- 5949.Park CO, Kupper TS. The emerging role of resident memory T cells in protective595immunity and inflammatory disease. Nat Med 2015; 21:688-97.
- 59610.Clark RA. Resident memory T cells in human health and disease. Sci Transl Med5972015; 7:269rv1.
- 59811.Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted599responses of intraepidermal T cells. Eur J Dermatol 2007; 17:201-8.
- Clark RA, Watanabe R, Teague JE, Schlapbach C, Tawa MC, Adams N, et al. Skin
 effector memory T cells do not recirculate and provide immune protection in
 alemtuzumab-treated CTCL patients. Sci Transl Med 2012; 4:117ra7.
- Watanabe R, Gehad A, Yang C, Scott LL, Teague JE, Schlapbach C, et al. Human skin
 is protected by four functionally and phenotypically discrete populations of
 resident and recirculating memory T cells. Sci Transl Med 2015; 7:279ra39.
- Moed H, Boorsma DM, Tensen CP, Flier J, Jonker MJ, Stoof TJ, et al. Increased
 CCL27-CCR10 expression in allergic contact dermatitis: implications for local skin
 memory. J Pathol 2004; 204:39-46.
- Scheper RJ, von Blomberg M, Boerrigter GH, Bruynzeel D, van Dinther A, Vos A.
 Induction of immunological memory in the skin. Role of local T cell retention. Clin
 Exp Immunol 1983; 51:141-8.
- 612 16. Gaide O, Emerson RO, Jiang X, Gulati N, Nizza S, Desmarais C, et al. Common clonal
 613 origin of central and resident memory T cells following skin immunization. Nat
 614 Med 2015; 21:647-53.

- 615 17. Schmidt JD, Ahlstrom MG, Johansen JD, Dyring-Andersen B, Agerbeck C, Nielsen
 616 MM, et al. Rapid allergen-induced interleukin-17 and interferon-gamma secretion
 617 by skin-resident memory CD8+ T cells. Contact Dermatitis 2017; 76:218-27.
- Brunner PM, Emerson RO, Tipton C, Garcet S, Khattri S, Coats I, et al. Nonlesional
 atopic dermatitis skin shares similar T-cell clones with lesional tissues. Allergy
 2017.
- 621 19. Vocanson M, Hennino A, Rozieres A, Poyet G, Nicolas JF. Effector and regulatory
 622 mechanisms in allergic contact dermatitis. Allergy 2009; 64:1699-714.
- 623 20. Garrigue JL, Nicolas JF, Fraginals R, Benezra C, Bour H, Schmitt D. Optimization of
 624 the mouse ear swelling test for in vivo and in vitro studies of weak contact
 625 sensitizers. Contact Dermatitis 1994; 30:231-7.
- Mueller SN, Gebhardt T, Carbone FR, Heath WR. Memory T cell subsets, migration
 patterns, and tissue residence. Annu Rev Immunol 2013; 31:137-61.
- Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat
 Rev Immunol 2015; 15:486-99.
- 630 23. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236:219-42.
- Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory
 Receptors with Specialized Functions in Immune Regulation. Immunity 2016;
 44:989-1004.
- 63525.Morris AB, Adams LE, Ford ML. Influence of T Cell Coinhibitory Molecules on636CD8(+) Recall Responses. Front Immunol 2018; 9:1810.
- 637 26. Cho JH, Sprent J. TCR tuning of T cell subsets. Immunol Rev 2018; 283:129-37.
- 638 27. Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD96: new
 639 checkpoint receptor targets for cancer immunotherapy. Immunol Rev 2017;
 640 276:112-20.
- 641 28. Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer
 642 immunotherapy target. Immunol Rev 2017; 276:80-96.
- 64329.Cai G, Freeman GJ. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional644switch regulating T-cell activation. Immunol Rev 2009; 229:244-58.
- 64530.Nowak EC, Lines JL, Varn FS, Deng J, Sarde A, Mabaera R, et al. Immunoregulatory646functions of VISTA. Immunol Rev 2017; 276:66-79.
- Mackay LK, Stock AT, Ma JZ, Jones CM, Kent SJ, Mueller SN, et al. Long-lived
 epithelial immunity by tissue-resident memory T (TRM) cells in the absence of
 persisting local antigen presentation. Proc Natl Acad Sci U S A 2012; 109:7037-42.
- Martin S, Ortmann B, Pflugfelder U, Birsner U, Weltzien HU. Role of haptenanchoring peptides in defining hapten-epitopes for MHC-restricted cytotoxic T
 cells. Cross-reactive TNP-determinants on different peptides. J Immunol 1992;
 149:2569-75.
- Khan TN, Mooster JL, Kilgore AM, Osborn JF, Nolz JC. Local antigen in
 nonlymphoid tissue promotes resident memory CD8+ T cell formation during
 viral infection. J Exp Med 2016; 213:951-66.
- Mackay LK, Wakim L, van Vliet CJ, Jones CM, Mueller SN, Bannard O, et al.
 Maintenance of T cell function in the face of chronic antigen stimulation and repeated reactivation for a latent virus infection. J Immunol 2012; 188:2173-8.
- Muschaweckh A, Buchholz VR, Fellenzer A, Hessel C, Konig PA, Tao S, et al.
 Antigen-dependent competition shapes the local repertoire of tissue-resident memory CD8+ T cells. J Exp Med 2016; 213:3075-86.

- 663 36. Peng H, Jiang X, Chen Y, Sojka DK, Wei H, Gao X, et al. Liver-resident NK cells
 664 confer adaptive immunity in skin-contact inflammation. J Clin Invest 2013;
 665 123:1444-56.
- Rouzaire P, Luci C, Blasco E, Bienvenu J, Walzer T, Nicolas JF, et al. Natural killer
 cells and T cells induce different types of skin reactions during recall responses
 to haptens. Eur J Immunol 2012; 42:80-8.
- 669 38. Hartwig T, Pantelyushin S, Croxford AL, Kulig P, Becher B. Dermal IL-17670 producing gammadelta T cells establish long-lived memory in the skin. Eur J
 671 Immunol 2015; 45:3022-33.
- Kohlmeier JE, Cookenham T, Roberts AD, Miller SC, Woodland DL. Type I interferons regulate cytolytic activity of memory CD8(+) T cells in the lung airways during respiratory virus challenge. Immunity 2010; 33:96-105.
- 40. Soudja SM, Ruiz AL, Marie JC, Lauvau G. Inflammatory monocytes activate
 memory CD8(+) T and innate NK lymphocytes independent of cognate antigen
 during microbial pathogen invasion. Immunity 2012; 37:549-62.
- 67841.Raue HP, Beadling C, Haun J, Slifka MK. Cytokine-mediated programmed679proliferation of virus-specific CD8(+) memory T cells. Immunity 2013; 38:131-9.
- 42. Mascre G, Dekoninck S, Drogat B, Youssef KK, Brohee S, Sotiropoulou PA, et al.
 Distinct contribution of stem and progenitor cells to epidermal maintenance.
 Nature 2012; 489:257-62.
- 43. Sada A, Jacob F, Leung E, Wang S, White BS, Shalloway D, et al. Defining the
 cellular lineage hierarchy in the interfollicular epidermis of adult skin. Nat Cell
 Biol 2016; 18:619-31.
- Roy E, Neufeld Z, Cerone L, Wong HY, Hodgson S, Livet J, et al. Bimodal behaviour
 of interfollicular epidermal progenitors regulated by hair follicle position and
 cycling. EMBO J 2016; 35:2658-70.
- 689 45. Cunningham AL, Diefenbach RJ, Miranda-Saksena M, Bosnjak L, Kim M, Jones C, et
 690 al. The cycle of human herpes simplex virus infection: virus transport and
 691 immune control. J Infect Dis 2006; 194 Suppl 1:S11-8.
- 692 46. Davies B, Prier JE, Jones CM, Gebhardt T, Carbone FR, Mackay LK. Cutting Edge:
 693 Tissue-Resident Memory T Cells Generated by Multiple Immunizations or
 694 Localized Deposition Provide Enhanced Immunity. J Immunol 2017; 198:2233-7.
- 695 47. Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpreville V, et al.
 696 CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident
 697 memory T cells and a prognostic factor for survival in lung cancer patients. J
 698 Immunol 2015; 194:3475-86.
- Enamorado M, Iborra S, Priego E, Cueto FJ, Quintana JA, Martinez-Cano S, et al.
 Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8(+) T cells. Nat Commun 2017; 8:16073.
- Pallett LJ, Davies J, Colbeck EJ, Robertson F, Hansi N, Easom NJW, et al. IL-2(high)
 tissue-resident T cells in the human liver: Sentinels for hepatotropic infection. J
 Exp Med 2017; 214:1567-80.
- 70550.Wakim LM, Woodward-Davis A, Liu R, Hu Y, Villadangos J, Smyth G, et al. The706molecular signature of tissue resident memory CD8 T cells isolated from the707brain. J Immunol 2012; 189:3462-71.
- 51. Yoshizawa A, Bi K, Keskin DB, Zhang G, Reinhold B, Reinherz EL. TCR-pMHC
 encounter differentially regulates transcriptomes of tissue-resident CD8 T cells.
 Eur J Immunol 2018; 48:128-50.

- 52. Shwetank, Abdelsamed HA, Frost EL, Schmitz HM, Mockus TE, Youngblood BA, et
 al. Maintenance of PD-1 on brain-resident memory CD8 T cells is antigen
 independent. Immunol Cell Biol 2017; 95:953-9.
- 53. Boldison J, Chu CJ, Copland DA, Lait PJ, Khera TK, Dick AD, et al. Tissue-resident
 exhausted effector memory CD8+ T cells accumulate in the retina during chronic
 experimental autoimmune uveoretinitis. J Immunol 2014; 192:4541-50.
- 54. Kumar BV, Ma W, Miron M, Granot T, Guyer RS, Carpenter DJ, et al. Human
 Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and
 Functional Signatures in Lymphoid and Mucosal Sites. Cell Rep 2017; 20:2921-34.
- For the persistence, vigilance and control of human CD8+ lung-resident memory T cells.
 Nat Immunol 2016; 17:1467-78.
- 56. Petrelli A, Mijnheer G, van Konijnenburg DPH, van der Wal MM, Giovannone B,
 Mocholi E, et al. PD-1+CD8+ T cells are clonally expanding effectors in human
 chronic inflammation. J Clin Invest 2018.
- 57. Adachi T, Kobayashi T, Sugihara E, Yamada T, Ikuta K, Pittaluga S, et al. Hair
 follicle-derived IL-7 and IL-15 mediate skin-resident memory T cell homeostasis
 and lymphoma. Nat Med 2015; 21:1272-9.
- 58. Mohammed J, Beura LK, Bobr A, Astry B, Chicoine B, Kashem SW, et al. Stromal
 cells control the epithelial residence of DCs and memory T cells by regulated
 activation of TGF-beta. Nat Immunol 2016; 17:414-21.
- 732





Figure 1

B






Figure 2




Figure 3






Figure 4










Figure 6



Inhibitory checkpoint receptors control CD8+ resident memory T cells to prevent skin allergy

